Treatment of triple-negative metastatic breast cancer: Toward individualized targeted treatments or chemosensitization?

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Berrada, N ^a   Delaloge, S ^a   Andre F ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Alkylating agents; Molecular alterations; Targeted agents; Triple negative breast cancers

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRCA1 PROTEIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GAMMA SECRETASE INHIBITOR; GDC 0449; GEMCITABINE; IXABEPILONE; MAMMALIAN TARGET OF RAPAMYCIN; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; NAVELBINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NOTCH RECEPTOR; OLAPARIB; PACLITAXEL; PROGESTERONE RECEPTOR; RO 4929097; SUNITINIB; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DNA REPAIR; DRUG RESPONSE; DRUG SCREENING; DRUG SENSITIZATION; DRUG TARGETING; HUMAN; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; STEM CELL; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 78649389607     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq279     Document Type: Conference Paper

References (46)

1. Taylor R, Davis P, Boyages J. Long-term survival of women with breast cancer in New South Wales. Eur J Cancer 2003; 39: 215-222.
2. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
3. Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393-10398.
4. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
5. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
6. Bidard FC, Conforti R, Boulet T et al. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers Ann Oncol 2007; 18: 1285-1286.
7. Kreike B, van Kouwenhove M, Horlings H et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9: R65.
8. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502.
9. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11: 5678-5685.
10. Conforti R, Boulet T, Tomasic G et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann Oncol 2007; 18: 1477-1483.
11. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
12. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
13. Martín M, Ruiz A, Muñoz M et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007; 8: 219-225.
14. Albain KS, Nag SM, Calderillo-Ruiz G et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008; 26: 3950-3957.
15. Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat 2010; 121: 261-271.
16. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
17. Miles D, Chan A, Romieu G et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008; 26 (15 Suppl): abstract LBA1011.
18. Heitz F, Harter P, Lueck H-J et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009; 45: 2792-2798.
19. Cardoso F, Bedard PL, Winer EP et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 2009; 101: 1174-1181.
20. Blum JL, Beveridge R, Robert N et al. ABI-007 nanoparticle paclitaxel: demonstration of anti-tumor activity in taxane-refractory metastatic breast cancer. ASCO Annual Meeting 2003 abstract 64.
21. Thomas EA, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25: 5210-5217.
22. Robert NJ, Dieras J, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009 27(15 Suppl); abstract 1005.
23. Brufsky A, Bondarenko IN, Smirnov V et al. RIBBON-2: a randomized, double-blind, placebo-controlled, Phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Cancer Res 2009; 69 (24 Suppl): abstract 42.
24. Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010; 28: 1145-1153.
25. O'Shaughnessy J, Osborne C, Pippen J et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial. J Clin Oncol 2009; 27 (18 Suppl): abstract 3.
26. Gronwald J, Byrski T, Huzarski T et al. Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. J Clin Oncol 2009; 27 (15 Suppl): abstract 502.
27. Delaloge S, Tedesco KL, Blum J et al. Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts). J Clin Oncol 2009; 27 (15 Suppl): abstract 1010.
28. Jones C, Mackay A, Grigoriadis A et al. Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res 2004; 64: 3037-3045.
29. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
30. Matros E, Wang ZC, Lodeiro G et al. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 2005; 91: 179-186.
31. Turner N, Lambros MB, Horlings HM et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29: 2013-2023.
32. Andre F, Dessen P, Job B et al. Functional pathways analyses to identify candidate therapeutic targets in triple-negative breast cancer. J Clin Oncol 2009; 27 (15 Suppl): abstract 569.
33. Andre F, Job B, Dessen P et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009; 15: 441-451.
34. Marty B, Maire V, Gravier E et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008; 10: R101.
35. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
36. Desmedt C, Haibe-Kains B, Wirapati P et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14: 5158-5165.
37. Teschendorff AE, Miremadi A, Pinder SE et al. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007; 8: R157.
38. Niemeier LA, Dabbs DJ, Beriwal S et al. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2010; 23: 205-212.
39. Park SY, Lee HE, Li H et al. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 2010; 16: 876-887.
40. Tutt A, Robson M, Garber JE et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009; 27 (18 Suppl); abstract CRA501.
41. Carey LA, Rugo HS, Marcom PK et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. J Clin Oncol 2008; 26 (15 Suppl); abstract 1009.
42. Harbeck N, Schmidt M, Harter P et al. BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than two prior chemotherapies. Cancer Res 2009; 69 (24 Suppl): abstract 5062.
43. Beuvink I, Boulay A, Fumagalli S et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005; 120: 747-759.
44. Burstein HJ, Elias AD, Rugo HS et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26: 1810-1816.
45. Kobune M, Takimoto R, Murase K et al. Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells. Cancer Sci 2009; 100: 948-955.
46. http://clinicaltrials.gov/ct2/results?term=RO4929097++ (27 July 2010, date last accessed).